JP2010514835A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010514835A5 JP2010514835A5 JP2009544484A JP2009544484A JP2010514835A5 JP 2010514835 A5 JP2010514835 A5 JP 2010514835A5 JP 2009544484 A JP2009544484 A JP 2009544484A JP 2009544484 A JP2009544484 A JP 2009544484A JP 2010514835 A5 JP2010514835 A5 JP 2010514835A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- compound according
- linking residue
- group
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 38
- 108090000765 processed proteins & peptides Proteins 0.000 claims 10
- 238000006467 substitution reaction Methods 0.000 claims 9
- AHUAWUAHWZIPJC-UHFFFAOYSA-M sodium;2-(3-hexoxy-2-hydroxypropoxy)benzoate Chemical compound [Na+].CCCCCCOCC(O)COC1=CC=CC=C1C([O-])=O AHUAWUAHWZIPJC-UHFFFAOYSA-M 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 claims 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims 1
- 108010032595 Antibody Binding Sites Proteins 0.000 claims 1
- 229940123208 Biguanide Drugs 0.000 claims 1
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 claims 1
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 claims 1
- 229940100389 Sulfonylurea Drugs 0.000 claims 1
- 229940123464 Thiazolidinedione Drugs 0.000 claims 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims 1
- 150000004283 biguanides Chemical class 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 230000003197 catalytic effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229950004994 meglitinide Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000000269 nucleophilic effect Effects 0.000 claims 1
- 150000001467 thiazolidinediones Chemical class 0.000 claims 1
- 0 CC(C)(C(*)=O)NC([C@@](*)Cc1cnc[n]1)=O Chemical compound CC(C)(C(*)=O)NC([C@@](*)Cc1cnc[n]1)=O 0.000 description 2
- KIDRGEYNFGIWLV-BYPYZUCNSA-N C[N-](C)([C@H](C(N)=O)O)P Chemical compound C[N-](C)([C@H](C(N)=O)O)P KIDRGEYNFGIWLV-BYPYZUCNSA-N 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87904807P | 2007-01-05 | 2007-01-05 | |
| US60/879,048 | 2007-01-05 | ||
| US93983107P | 2007-05-23 | 2007-05-23 | |
| US60/939,831 | 2007-05-23 | ||
| US94531907P | 2007-06-20 | 2007-06-20 | |
| US60/945,319 | 2007-06-20 | ||
| PCT/IE2008/000001 WO2008081418A1 (en) | 2007-01-05 | 2008-01-07 | Glucagon-like protein-1 receptor (glp-1r) agonist compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012089113A Division JP2012184232A (ja) | 2007-01-05 | 2012-04-10 | グルカゴン様タンパク質１受容体（ｇｌｐ−１ｒ）アゴニスト化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010514835A JP2010514835A (ja) | 2010-05-06 |
| JP2010514835A5 true JP2010514835A5 (enExample) | 2011-01-06 |
| JP5009376B2 JP5009376B2 (ja) | 2012-08-22 |
Family
ID=39313161
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009544484A Expired - Fee Related JP5009376B2 (ja) | 2007-01-05 | 2008-01-07 | グルカゴン様タンパク質１受容体（ｇｌｐ−１ｒ）アゴニスト化合物 |
| JP2012089113A Pending JP2012184232A (ja) | 2007-01-05 | 2012-04-10 | グルカゴン様タンパク質１受容体（ｇｌｐ−１ｒ）アゴニスト化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012089113A Pending JP2012184232A (ja) | 2007-01-05 | 2012-04-10 | グルカゴン様タンパク質１受容体（ｇｌｐ−１ｒ）アゴニスト化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20090098130A1 (enExample) |
| EP (1) | EP2118131A1 (enExample) |
| JP (2) | JP5009376B2 (enExample) |
| KR (2) | KR20120083510A (enExample) |
| AU (1) | AU2008203641B2 (enExample) |
| BR (1) | BRPI0806308A2 (enExample) |
| CA (1) | CA2674112A1 (enExample) |
| MX (1) | MX2009007290A (enExample) |
| NZ (1) | NZ577686A (enExample) |
| WO (1) | WO2008081418A1 (enExample) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090098130A1 (en) * | 2007-01-05 | 2009-04-16 | Bradshaw Curt W | Glucagon-like protein-1 receptor (glp-1r) agonist compounds |
| JP2011511778A (ja) | 2008-01-30 | 2011-04-14 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション | エステルに基づいたペプチドプロドラッグ |
| US8293714B2 (en) | 2008-05-05 | 2012-10-23 | Covx Technology Ireland, Ltd. | Anti-angiogenic compounds |
| US20120148586A1 (en) | 2009-08-27 | 2012-06-14 | Joyce Ching Tsu Chou | Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders |
| CA2784757A1 (en) * | 2009-12-16 | 2011-07-07 | Novo Nordisk A/S | Double-acylated glp-1 derivatives |
| US8765920B2 (en) | 2009-12-23 | 2014-07-01 | The Scripps Research Institute | Tyrosine bioconjugation through aqueous Ene-like reactions |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| DE102010015123A1 (de) | 2010-04-16 | 2011-10-20 | Sanofi-Aventis Deutschland Gmbh | Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| JP5912112B2 (ja) | 2010-06-24 | 2016-04-27 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | アミド系インスリンプロドラッグ |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| CN103096933A (zh) | 2010-07-12 | 2013-05-08 | CovX科技爱尔兰有限公司 | 多功能抗体缀合物 |
| EP3124039B1 (en) | 2010-08-20 | 2018-01-31 | Wyeth LLC | Designer osteogenic proteins |
| US9688735B2 (en) | 2010-08-20 | 2017-06-27 | Wyeth Llc | Designer osteogenic proteins |
| RU2013118441A (ru) * | 2010-11-05 | 2014-12-10 | КовЭкс Текнолоджиз Айэлэнд Лимитед | Антидиабетические соединения |
| WO2012169798A2 (en) | 2011-06-10 | 2012-12-13 | Hanmi Science Co., Ltd. | Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same |
| EP3502129B1 (en) | 2011-06-17 | 2021-04-07 | Hanmi Science Co., Ltd. | A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| JP6392123B2 (ja) | 2011-12-20 | 2018-09-19 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | 糖尿病治療のためのｃｔｐ系インスリンアナローグ |
| SG11201403324TA (en) * | 2011-12-20 | 2014-07-30 | Pfizer | Improved processes for preparing peptide conjugates and linkers |
| AU2012356219B2 (en) | 2011-12-22 | 2016-03-31 | Covx Technologies Ireland Limited | Anti-diabetic compounds |
| WO2013105013A1 (en) | 2012-01-09 | 2013-07-18 | Covx Technologies Ireland Limited | Mutant antibodies and conjugation thereof |
| CA2875743A1 (en) * | 2012-06-14 | 2013-12-19 | Sanofi | Exendin-4 peptide analogues |
| KR101968344B1 (ko) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
| EP2900255B1 (en) * | 2012-09-26 | 2019-01-30 | Indiana University Research and Technology Corporation | Insulin analog dimers |
| UA116217C2 (uk) * | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| US20150297573A1 (en) | 2012-10-24 | 2015-10-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING Beta-CELL SURVIVAL |
| CA2890324C (en) | 2012-11-06 | 2021-02-23 | Hanmi Pharm. Co., Ltd. | Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment |
| KR101993393B1 (ko) | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
| EP2934568B1 (en) | 2012-12-21 | 2017-10-18 | Sanofi | Dual glp1/gip or trigonal glp1/gip/glucagon agonists |
| KR20150131213A (ko) | 2013-03-14 | 2015-11-24 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 인슐린-인크레틴 접합체들 |
| CN104371019B (zh) | 2013-08-13 | 2019-09-10 | 鸿运华宁（杭州）生物医药有限公司 | 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质 |
| EP3080152A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Non-acylated exendin-4 peptide analogues |
| WO2015086731A1 (en) * | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists |
| WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| TW201609797A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／升糖素受體促效劑 |
| EP3080154B1 (en) * | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
| AR098614A1 (es) * | 2013-12-18 | 2016-06-01 | Lilly Co Eli | Compuesto para el tratamiento de hipoglicemia severa |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| TWI772252B (zh) | 2014-09-16 | 2022-08-01 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
| ES2947409T3 (es) | 2014-09-24 | 2023-08-08 | Univ Indiana Res & Tech Corp | Profármacos de insulina a base de amida lipídica |
| WO2016049190A1 (en) | 2014-09-24 | 2016-03-31 | Indiana University Research And Technology Corporation | Incretin-insulin conjugates |
| KR102418477B1 (ko) * | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
| EP3575314B1 (en) | 2014-12-30 | 2024-02-14 | Hanmi Pharm. Co., Ltd. | Glucagon derivative |
| ES2833099T3 (es) | 2015-02-11 | 2021-06-14 | Gmax Biopharm Llc | Preparación de disolución estabilizada de una proteína de fusión de un anticuerpo de GLP-1R farmacéutica |
| ES2805743T3 (es) | 2015-03-24 | 2021-02-15 | Inst Nat Sante Rech Med | Método y composición farmacéutica para uso en el tratamiento de la diabetes |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| WO2016198604A1 (en) * | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as dual glp-1 /glucagon receptor agonists |
| MA49545B1 (fr) | 2015-06-30 | 2022-03-31 | Hanmi Pharm Ind Co Ltd | Dérivé de glucagon et composition comprenant un conjugué à action prolongée de celui-ci |
| TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物 |
| CA3223591A1 (en) | 2015-12-23 | 2017-06-29 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists |
| CN115920077B (zh) | 2015-12-31 | 2025-07-04 | 韩美药品株式会社 | 胰高血糖素/glp-1/gip受体三重激动剂的长效缀合物 |
| CA3029518A1 (en) | 2016-06-29 | 2018-01-04 | Hanmi Pharm. Co., Ltd. | Glucagon derivative, conjugate thereof, composition comprising same, and therapeutic use thereof |
| JOP20190177A1 (ar) * | 2017-01-17 | 2019-07-16 | Amgen Inc | طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr) |
| MX2019013919A (es) * | 2017-06-20 | 2020-01-21 | Amgen Inc | Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1. |
| EP4353250A3 (en) | 2017-06-21 | 2024-06-19 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (gipr)/glp-1 receptor agonist fusion proteins |
| JP7495420B2 (ja) | 2019-02-20 | 2024-06-04 | ノヴォ ノルディスク アー／エス | アミノアシル－ｔＲＮＡ合成酵素およびこの使用 |
| CN113493504B (zh) * | 2020-03-18 | 2024-02-27 | 深圳纳福生物医药有限公司 | GIP-Exendin-4嵌合肽的分子改构及其二聚体在治疗糖尿病中的应用 |
| CA3199733A1 (en) * | 2020-12-11 | 2022-06-16 | Stephen Robert Bloom | Novel compounds |
| MX2023009550A (es) * | 2021-02-16 | 2023-08-22 | Univ Indiana Res & Tech Corp | Antagonistas del receptor del peptido-1 tipo glucagon. |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3719667A (en) * | 1970-08-24 | 1973-03-06 | Lilly Co Eli | Epimerization of 6-acylamido and 6-imido penicillin sulfoxide esters |
| US3840556A (en) * | 1971-05-28 | 1974-10-08 | Lilly Co Eli | Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby |
| US5567610A (en) * | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US5216132A (en) * | 1990-01-12 | 1993-06-01 | Protein Design Labs, Inc. | Soluble t-cell antigen receptor chimeric antigens |
| ATE155482T1 (de) * | 1990-04-06 | 1997-08-15 | Jolla Cancer Res Found | Verfahren und verbindung zur behandlung von thrombose |
| US5229275A (en) * | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5565332A (en) * | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US6080840A (en) * | 1992-01-17 | 2000-06-27 | Slanetz; Alfred E. | Soluble T cell receptors |
| US5573905A (en) * | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| US5424286A (en) * | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
| US5733757A (en) * | 1995-12-15 | 1998-03-31 | The Scripps Research Institute | Aldolase catalytic antibody |
| US5739277A (en) * | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) * | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| GB9722131D0 (en) * | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| US6326176B1 (en) * | 1997-12-18 | 2001-12-04 | The Scripps Research Institute | Aldol condensations by catalytic antibodies |
| US6924264B1 (en) * | 1999-04-30 | 2005-08-02 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
| IL146450A0 (en) * | 1999-05-14 | 2002-07-25 | Univ Mcgill | Protein-protein interactions and methods for identifying interacting proteins and the amino acid sequence at the site of interaction |
| CA2501421A1 (en) * | 1999-05-17 | 2000-11-23 | Conjuchem Inc. | Long lasting exendin-4 |
| US6294374B1 (en) * | 1999-10-08 | 2001-09-25 | The Scripps Research Institute | Use of catalytic antibodies for synthesizing epothilone |
| KR100942864B1 (ko) * | 2000-12-07 | 2010-02-17 | 일라이 릴리 앤드 캄파니 | Ｇｌｐ-1 융합 단백질 |
| US20030045477A1 (en) * | 2001-07-26 | 2003-03-06 | Fortuna Haviv | Peptides having antiangiogenic activity |
| DK1641823T3 (da) * | 2003-06-12 | 2011-12-12 | Lilly Co Eli | GLP-1-analog fusionsproteiner |
| ES2298785T3 (es) * | 2003-06-12 | 2008-05-16 | Eli Lilly And Company | Proteinas de fusion. |
| WO2005015595A1 (ja) * | 2003-08-07 | 2005-02-17 | Fujitsu Limited | マイクロスイッチング素子およびその製造方法 |
| JP2007537142A (ja) * | 2003-12-18 | 2007-12-20 | ノボ ノルディスク アクティーゼルスカブ | アルブミン様物質に結合した新規のｇｌｐ−１類似物 |
| DK1797127T3 (en) * | 2004-09-24 | 2017-10-02 | Amgen Inc | Modified Fc molecules |
| JP5167473B2 (ja) * | 2005-03-03 | 2013-03-21 | コヴェックス・テクノロジーズ・アイルランド・リミテッド | 抗血管新生化合物 |
| GB2427360A (en) * | 2005-06-22 | 2006-12-27 | Complex Biosystems Gmbh | Aliphatic prodrug linker |
| JP4897050B2 (ja) * | 2006-11-10 | 2012-03-14 | コヴェックス・テクノロジーズ・アイルランド・リミテッド | 抗血管形成化合物 |
| US20090098130A1 (en) * | 2007-01-05 | 2009-04-16 | Bradshaw Curt W | Glucagon-like protein-1 receptor (glp-1r) agonist compounds |
| JP2010538069A (ja) * | 2007-09-07 | 2010-12-09 | イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ | エキセンディン−４およびエキセンディン−３の類似体 |
-
2008
- 2008-01-04 US US11/969,850 patent/US20090098130A1/en not_active Abandoned
- 2008-01-07 JP JP2009544484A patent/JP5009376B2/ja not_active Expired - Fee Related
- 2008-01-07 MX MX2009007290A patent/MX2009007290A/es active IP Right Grant
- 2008-01-07 EP EP08702600A patent/EP2118131A1/en not_active Withdrawn
- 2008-01-07 CA CA002674112A patent/CA2674112A1/en not_active Abandoned
- 2008-01-07 NZ NZ577686A patent/NZ577686A/en not_active IP Right Cessation
- 2008-01-07 KR KR1020127014446A patent/KR20120083510A/ko not_active Ceased
- 2008-01-07 BR BRPI0806308-7A patent/BRPI0806308A2/pt not_active IP Right Cessation
- 2008-01-07 AU AU2008203641A patent/AU2008203641B2/en not_active Ceased
- 2008-01-07 WO PCT/IE2008/000001 patent/WO2008081418A1/en not_active Ceased
- 2008-01-07 KR KR1020097013938A patent/KR101224335B1/ko not_active Expired - Fee Related
-
2012
- 2012-04-10 JP JP2012089113A patent/JP2012184232A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010514835A5 (enExample) | ||
| RU2432361C2 (ru) | Соединения агонисты рецептора глюкагоноподобного белка-1 (glp-1r) | |
| AU2016214978B2 (en) | Targeting constructs for delivery of payloads | |
| JP2011500725A5 (enExample) | ||
| RU2476441C2 (ru) | Cd19-связывающие средства и их применение | |
| JP2009225799A5 (enExample) | ||
| WO2013093720A3 (en) | Anti-diabetic compounds | |
| WO2023283629A1 (en) | Muscle targeting complexes and formulations thereof for treating facioscapulohumeral muscular dystrophy | |
| JP2012522512A5 (enExample) | ||
| RU2012157167A (ru) | Полифункциональные антительные конъюгаты | |
| AU2018203508A1 (en) | CD33 antibodies and use of same to treat cancer | |
| WO2008101231A3 (en) | Methods and compositions for treating and diagnosing kidney disease | |
| WO2007134037A3 (en) | Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments | |
| JP2011528710A5 (enExample) | ||
| JP2014522850A5 (enExample) | ||
| CN111712520A (zh) | 磷脂酰肌醇聚糖3抗体及其偶联物 | |
| SI2530091T1 (en) | Anti-dll3 antibody | |
| RU2012106200A (ru) | Агонисты рецептора глюкагоноподобного пептида-1 (glp-1r) для лечения аутоиммунных расстройств | |
| JPWO2020016662A5 (enExample) | ||
| JP2018510864A5 (enExample) | ||
| RS56298B1 (sr) | Antitelo koje vezuje il-17a i il-17f | |
| WO2007100385A3 (en) | Macrocyclic depsipeptide antibody-drug conjugates and methods | |
| JP2012522513A5 (enExample) | ||
| WO2007088129A3 (en) | Cyanine dye compounds linked to metal chelator for bi-modal diagnostic imaging | |
| WO2008056346B1 (en) | Anti-angiogenic compounds |